A new report from Healthsperien, prepared for the American Hospital Association, found that while the 340B program is still a minor portion of the drug industry revenue, its growth has provided significant benefits to a large number of underserved U.S. patients and communities.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
